Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

November 29, 2016

Study Completion Date

November 29, 2016

Conditions
Growth Hormone Deficiency With Pituitary Anomalies
Interventions
DRUG

Macimorelin

macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose

DRUG

Insulin

Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose

Trial Locations (27)

1030

Krankenanstalt Rudolfstiftung, Vienna

1090

Medical University & General Hospital of Vienna, AKH,, Vienna

10117

Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité, Berlin

11000

Clinical Centre of Serbia, Belgrade

15706

Hospital de Conxo, Santiago de Compostela

20149

San Luca Hospital, Milan

21000

Clinical Centre of Vojvodina, Novi Sad

33600

Hôpital Haut-Lévêque, Pessac

35033

University Hospital Marburg, Marburg

52074

RWTH Aachen University Hospital, Aachen

69677

CHU de Lyon HCL-GH Est, Bron

77030

Baylor College of Medicine-Endocrinology, Houston

78731

Texas Diabetes and Endocrinology, Austin

80336

Klinikum der LMU München, Munich

80804

Max Planck Institut, Munich

90509

Harbor UCLA Medical Center, Torrance

94270

GHU Paris-Sud - Hôpital de Bicêtre, Le Kremlin-Bicêtre

98108

VA Puget Sound Health Care System, Seattle

98122

Swedish Medical Center - Cherry Hill, Seattle

82-300

Centrum Kliniczno-Badawcze, Elblag

40-611

Centrum Medyczne Angelius Provita, Katowice

02-106

Phase I - MTZ Clinical Research Sp. z o.o., Warsaw

51-685

Wromedica, Wroclaw

08026

Hospital de Sant Pau, Barcelona

08035

Hospital Universitari Vall d' Hebron, Barcelona

EC1A 7BE

St Bartholomew's Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY